China Universal Asset Management Co. Ltd. Makes New Investment in Stryker Corporation $SYK

China Universal Asset Management Co. Ltd. bought a new stake in Stryker Corporation (NYSE:SYK) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 2,000 shares of the medical technology company’s stock, valued at approximately $741,000.

Other institutional investors have also modified their holdings of the company. Kovack Advisors Inc. boosted its stake in Stryker by 3.6% during the 2nd quarter. Kovack Advisors Inc. now owns 771 shares of the medical technology company’s stock valued at $305,000 after purchasing an additional 27 shares during the period. Armstrong Advisory Group Inc. raised its holdings in shares of Stryker by 12.3% during the third quarter. Armstrong Advisory Group Inc. now owns 247 shares of the medical technology company’s stock valued at $91,000 after buying an additional 27 shares during the last quarter. Venturi Wealth Management LLC boosted its position in shares of Stryker by 1.4% during the third quarter. Venturi Wealth Management LLC now owns 1,904 shares of the medical technology company’s stock worth $704,000 after buying an additional 27 shares during the period. Patriot Financial Group Insurance Agency LLC grew its holdings in Stryker by 3.9% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 745 shares of the medical technology company’s stock worth $275,000 after buying an additional 28 shares in the last quarter. Finally, Wolff Wiese Magana LLC grew its holdings in Stryker by 2.3% in the 3rd quarter. Wolff Wiese Magana LLC now owns 1,271 shares of the medical technology company’s stock worth $470,000 after buying an additional 28 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the sale, the director owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.90% of the company’s stock.

Stryker Stock Up 2.0%

SYK stock opened at $380.15 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. The firm has a market cap of $145.48 billion, a PE ratio of 45.26, a P/E/G ratio of 2.18 and a beta of 0.87. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $404.87. The firm has a 50 day simple moving average of $360.05 and a 200 day simple moving average of $368.95.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.40 by $0.07. The company had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm’s revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.01 earnings per share. Equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is 41.90%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on SYK shares. Citigroup reiterated a “market outperform” rating on shares of Stryker in a research report on Friday, January 30th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Stryker in a report on Monday, December 22nd. Truist Financial lowered their target price on shares of Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a research note on Thursday, December 18th. Barclays reaffirmed an “overweight” rating and issued a $469.00 price target on shares of Stryker in a research note on Monday, February 2nd. Finally, Raymond James Financial upgraded shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price objective for the company in a report on Tuesday, January 6th. Thirteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average price target of $426.94.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.